An Open-Label, Multi-Center Study of LJPC‑501 in Pediatric Patients Who Remain Hypotensive Despite Receiving Fluid Therapy and Vasopressor Therapy
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2018
At a glance
- Drugs LJPC 501 (Primary)
- Indications Hypotension
- Focus Therapeutic Use
- Sponsors La Jolla Pharmaceutical Company
- 31 Aug 2018 Biomarkers information updated
- 06 Aug 2018 Status changed from recruiting to completed.
- 21 Feb 2018 According to a La Jolla Pharmaceutical Company media release, the first pediatric patient has been treated in this trial.